Amprion’s owned or exclusively-licensed alpha-synuclein portfolio is particularly extensive. The portfolio currently includes multiple allowed and/or issued patents in the United States, EU, Japan, UK, Korea, Singapore, Australia, Israel, Canada, and Mexico, with applications pending in India, China, Hong Kong, and Brazil. Amprion also has an issued US patent and pending applications worldwide directed to Amprion’s proprietary alpha-synuclein SAA substrate plus other key components needed for robust, reliable and reproducible performance of the technology.”
SYNTap Biomarker Test performance characteristics.
The U.S. FDA awarded Amprion Breakthrough Device Designation.
We help accelerate personalized medicine through biomarker testing.
Neurodegenerative diseases affect individuals differently. For instance, ten patients can have ten different biomarker profiles. In addition, symptoms often overlap, leading to diagnostic challenges.
The SYNTap Test offers physicians a molecular tool to greatly improve diagnosis accuracy. Our goal is to develop personalized medicine through biomarker testing.
Amprion has some important news we need to share with you!
To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.
Old self-pay price: $1500.00. New self-pay price: $995.00
Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process